The GIP arm: the second incretin
On its own, GIP, the other incretin hormone, looked like a weak drug target, because its insulin effect is blunted in…
The forgotten incretin that turned out to matter
On its own, GIP, the other incretin hormone, looked like a weak drug target, because its insulin effect is blunted in type 2 diabetes. Then tirzepatide paired it with GLP-1 and outperformed GLP-1 alone, and GIP suddenly looked essential. Retatrutide keeps that GIP arm and adds glucagon on top, so understanding what GIP contributes is key to understanding why two receptors beat one.
This unit covers GIP biology, why its role was underrated, and the still-live scientific debate about whether you should activate or block the GIP receptor. That debate is genuinely unresolved, and it is a good example of how this field advances faster than its textbooks.
Key terms
The incretin nobody wanted
On its own GIP looked like a weak drug target, because in type 2 diabetes its insulin effect is significantly diminished, as one review puts it, through impaired beta-cell function. The picture changed when GIP was combined with GLP-1 and the pair beat GLP-1 alone in a head-to-head trial, a reversal worth appreciating before the biology.
The lesson is that a target dismissed in isolation can shine in combination. Retatrutide inherits the GIP arm precisely because the dual-agonist data made it credible, then asks whether adding a third receptor pushes further still.
AdvancedWhy GIP looked broken in diabetes
In type 2 diabetes the insulinotropic effect of GIP is significantly diminished through impaired beta-cell function, which is what made GIP look weak on its own. The stated case for combining it with GLP-1 is different and more practical: dose-related gastrointestinal effects limit how far a GLP-1 drug can be pushed, so agents that add an alternative pathway may expand the therapeutic index. No source this course holds shows that combination restores GIP responsiveness.